 Q BioMed Inc OTCQB:QBIO has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus COVID-19. The company announced in March that Mannin would receive up to C1.7 million worth of RD funding from the National Research Council of Canada Industrial Research Assistance Program NRC IRAP to support the preclinical development of a therapeutic, MAN-19, to treat Acute Respiratory Distress Syndrome ARDS in COVID-19 patients. 